{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:47:18Z","timestamp":1790765238304,"version":"4.1.0"},"reference-count":48,"publisher":"Hindawi Limited","issue":"5","license":[{"start":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T00:00:00Z","timestamp":1329264000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T00:00:00Z","timestamp":1329264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1111\/j.1365-2710.2012.01334.x","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T02:54:52Z","timestamp":1329360892000},"page":"588-593","source":"Crossref","is-referenced-by-count":43,"title":["<i>CYP2E1<\/i>,<i>GSTM1<\/i>and<i>GSTT1<\/i>genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity: a nested case-control study"],"prefix":"10.1155","volume":"37","author":[{"given":"S.-W.","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.-Z.","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-S.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.-R.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-Y.","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.-H.","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-Y.","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.-F.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-Y.","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2012,2,15]]},"reference":[{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB1|cit1","volume-title":"Global tuberculosis control: WHO Report 2010","author":"World Organization Health","year":"2010"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1164\/rccm.167.4.603","article-title":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: treatment of tuberculosis","volume":"167","author":"Blumberg","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/thx.53.7.536","article-title":"Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society","volume":"53","year":"1998","journal-title":"Thorax"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1164\/ajrccm.164.7.2109052","article-title":"Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers","volume":"164","author":"Burman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1164\/rccm.200510-1666ST","article-title":"An official ATS statement: hepatotoxicity of antituberculosis therapy","volume":"174","author":"Saukkonen","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/thx.51.2.132","article-title":"Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study","volume":"51","author":"Pande","year":"1996","journal-title":"Thorax"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB9|cit9","first-page":"119","article-title":"Hepatotoxicity of isoniazid and rifampin in children","volume":"21","author":"Rugmini","year":"1984","journal-title":"Indian Pediatr"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB10|cit10","first-page":"461","article-title":"Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis","volume":"118","author":"Gronhagen-Riska","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0377-1237(06)80155-3","article-title":"Risk factors of hepatotoxicity during anti-tuberculosis treatment","volume":"62","author":"Anand","year":"2006","journal-title":"Med J Armed Forces India"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1440-1843.2006.00941.x","article-title":"Antituberculosis drugs and hepatotoxicity","volume":"11","author":"Yew","year":"2006","journal-title":"Respirology"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(00)03137-8","article-title":"Idiosyncratic drug reactions: the reactive metabolite syndromes","volume":"356","author":"Knowles","year":"2000","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00130832-200108000-00007","article-title":"Reactive metabolites and their role in drug reactions","volume":"1","author":"Naisbitt","year":"2001","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/jhep.2002.32102","article-title":"Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis","volume":"35","author":"Huang","year":"2002","journal-title":"Hepatology"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.tube.2007.05.012","article-title":"Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis","volume":"87","author":"Cho","year":"2007","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB17|cit17","first-page":"622","article-title":"NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis","volume":"14","author":"Lee","year":"2010","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2217\/pgs.10.109","article-title":"Comment on: Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population","volume":"11","author":"Leiro-Fernandez","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2217\/pgs.09.66","article-title":"Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population","volume":"10","author":"Yamada","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1440-1746.2010.06355.x","article-title":"Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis","volume":"26","author":"Bose","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1053\/jhep.2003.50144","article-title":"Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis","volume":"37","author":"Huang","year":"2003","journal-title":"Hepatology"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1177\/147323001003800324","article-title":"Genetic polymorphisms of cytochrome P450 and glutathione S-transferase associated with antituberculosis drug-induced hepatotoxicity in Chinese tuberculosis patients","volume":"38","author":"Wang","year":"2010","journal-title":"J Int Med Res"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1046\/j.1440-1746.2001.02585.x","article-title":"Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 \u2018null\u2019 mutation","volume":"16","author":"Roy","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2007.02.009","article-title":"Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury","volume":"47","author":"Huang","year":"2007","journal-title":"J Hepatol"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/j.1478-3231.2008.01700.x","article-title":"Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population","volume":"28","author":"Leiro","year":"2008","journal-title":"Liver Int"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.7326\/0003-4819-84-2-181","article-title":"Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis","volume":"84","author":"Mitchell","year":"1976","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/14622416.9.3.311","article-title":"Pharmacogenomics of anti-TB drugs-related hepatotoxicity","volume":"9","author":"Roy","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1126\/science.7838","article-title":"Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat","volume":"193","author":"Nelson","year":"1976","journal-title":"Science"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB29|cit29","first-page":"467","article-title":"The association between NAT2 polymorphism and anti-tuberculosis drug-induced hepatitis","volume":"18","author":"Wu","year":"2010","journal-title":"Chin J Dig Dis"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB30|cit30","first-page":"266","article-title":"The effect of GSTM1 and GSTT1 gene mutations on anti-tuberculous drug induced hepatic injury","volume":"32","author":"Guo","year":"2009","journal-title":"Chinese J Tuberculosis Respiratory Dis"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2710.2009.01101.x","article-title":"GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs","volume":"35","author":"Chatterjee","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/1471-2458-10-267","article-title":"Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS)","volume":"10","author":"Xia","year":"2010","journal-title":"BMC Public Health"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB33|cit33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021836","article-title":"Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China","volume":"6","author":"Shang","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0168-8278(90)90124-A","article-title":"Criteria of drug-induced liver disorders. Report of an international consensus meeting","volume":"11","author":"Benichou","year":"1990","journal-title":"J Hepatol"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB35|cit35","volume-title":"The use of the WHO-UMC system for standardized case causality assessment","author":"World Organization Health","year":"2005"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2307\/2531050","article-title":"More on \u201cBiased selection of controls for case-control analyses of cohort studies\u201d","volume":"42","author":"Robins","year":"1986","journal-title":"Biometrics"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00008469-200306000-00007","article-title":"Association between CYP2E1 polymorphisms and susceptibility to prostate cancer","volume":"12","author":"Ferreira","year":"2003","journal-title":"Eur J Cancer Prev"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1093\/jnci\/88.24.1853","article-title":"Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders","volume":"88","author":"Hirvonen","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/oxfordjournals.jbchem.a124526","article-title":"Different regulation and expression of the human CYP2E1 gene due to the RsaI polymorphism in the 5\u2019-flanking region","volume":"116","author":"Watanabe","year":"1994","journal-title":"J Biochem"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1530-0277.1998.tb03884.x","article-title":"Association studies of polymorphisms of CYP2E1 gene in alcoholics with cirrhosis, antisocial personality, and normal controls","volume":"22","author":"Parsian","year":"1998","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1440-1746.2006.04197.x","article-title":"Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patients","volume":"21","author":"Roy","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0378-4274(99)00230-1","article-title":"Glutathione S-transferase: genetics and role in toxicology","volume":"113","author":"Strange","year":"2000","journal-title":"Toxicol Lett"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.canlet.2004.01.002","article-title":"GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking","volume":"208","author":"Schneider","year":"2004","journal-title":"Cancer Lett"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2217\/pgs.09.100","article-title":"Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis","volume":"10","author":"Kim","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB45|cit45","first-page":"321","article-title":"Difference in HLA-A*02 allele distribution between Han populations in south and north China","volume":"25","author":"Cheng","year":"2005","journal-title":"Academic J First Med Coll PLA"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/bdd.557","article-title":"The effect of pyrazinamide and rifampicin on isoniazid metabolism in rats","volume":"28","author":"De","year":"2007","journal-title":"Biopharm Drug Dispos"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1590\/S0074-02762011000600011","article-title":"Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients","volume":"106","author":"Teixeira","year":"2011","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1111\/j.1365-2710.2012.01334.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/clpt.2010.355","article-title":"A fresh look at the mechanism of isoniazid-induced hepatotoxicity","volume":"89","author":"Metushi","year":"2011","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2012.01334.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2710.2012.01334.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2710.2012.01334.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:04:30Z","timestamp":1671818670000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2710.2012.01334.x"}},"subtitle":["Metabolic genetic polymorphisms and susceptibility to antituberculosis drug-induced hepatotoxicity"],"short-title":[],"issued":{"date-parts":[[2012,2,15]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2710.2012.01334.x","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2,15]]}}}